Cargando…

Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16)

BACKGROUND: PIK3CA contributes to cell growth via the PI3K-AKT-mammalian target of rapamycin (mTOR) signaling pathway. Mutations in the pathway are frequently observed in solid tumors. We assessed the efficacy and safety of sirolimus, an mTOR inhibitor, in chemotherapy-refractory solid tumors with P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Byeon, Seonggyu, Kang, Myoung Joo, Choi, Yoon Ji, Kim, Yu Jung, Kim, Miso, Yun, Jina, Yi, Seong Yoon, Kim, Jin Young, Kim, Seung Tae, Lee, Jeeyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798137/ https://www.ncbi.nlm.nih.gov/pubmed/35117688 http://dx.doi.org/10.21037/tcr.2020.04.07

Ejemplares similares

Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer
por: Jung, Ki Sun, et al.
Publicado: (2017)

Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)
por: Kang, Eun Joo, et al.
Publicado: (2022)

Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum
por: Parker, Victoria E. R., et al.
Publicado: (2018)

Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07
por: Kim, Miso, et al.
Publicado: (2020)

Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01)
por: Lee, Yun-Gyoo, et al.
Publicado: (2023)

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
por: Yoon, Shinkyo, et al.
Publicado: (2022)

Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG‐RC20‐06
por: Sohn, Byeong Seok, et al.
Publicado: (2023)

ERRATUM: Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
por: Yoon, Shinkyo, et al.
Publicado: (2023)

Case Report: Kaposiform hemangioendothelioma with PIK3CA mutation successfully treated with sirolimus
por: Wang, Zuopeng, et al.
Publicado: (2023)

Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
por: Lee, Yun-Gyoo, et al.
Publicado: (2020)

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
por: Sim, Sung Hoon, et al.
Publicado: (2022)

Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
por: Choi, Yoon Ji, et al.
Publicado: (2018)

Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)
por: Lee, Yun-Gyoo, et al.
Publicado: (2022)

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
por: Kim, Hye Ryun, et al.
Publicado: (2016)

HLA-A*11:01:01:01, HLA-C*12:02:02:01-HLA-B*52:01:02:02, Age and Sex Are Associated With Severity of Japanese COVID-19 With Respiratory Failure
por: Khor, Seik-Soon, et al.
Publicado: (2021)

A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First‐line Therapy (KCSG ST10‐01)
por: Lee, Keun‐Wook, et al.
Publicado: (2018)

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20)
por: Kim, Jung Sun, et al.
Publicado: (2023)

Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
por: Kim, Joo Hoon, et al.
Publicado: (2016)

Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06)
por: Kim, Jung Sun, et al.
Publicado: (2023)

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
por: Park, In Hae, et al.
Publicado: (2019)

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07
por: Kim, Seung Tae, et al.
Publicado: (2022)

Early Time-Restricted Eating Reduces Weight and Improves Glycemic Response in Young Adults: A Pre-Post Single-Arm Intervention Study
por: Kim, JinA, et al.
Publicado: (2022)

Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease
por: Chen, Xiao, et al.
Publicado: (2022)

A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma
por: Byeon, Seonggyu, et al.
Publicado: (2016)

Comparison of Sirolimus and Paclitaxel-Eluting Stents for Complex Coronary Lesions: An Intravascular Ultrasound Study
por: Cho, Yun-Kyeong, et al.
Publicado: (2009)

Pik3ca is required for mouse uterine gland development and pregnancy
por: Chang, Hye Jin, et al.
Publicado: (2018)

Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer
por: Jang, Si-Hyong, et al.
Publicado: (2016)

Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study
por: Kim, Jin Won, et al.
Publicado: (2018)

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
por: Kim, Ju Sun, et al.
Publicado: (2017)

PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA
por: Kim, Seung Tae, et al.
Publicado: (2015)

Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
por: Hwang, In Gyu, et al.
Publicado: (2021)

Potent antitumor efficacy of human dental pulp stem cells armed with YSCH-01 oncolytic adenovirus
por: He, Xu, et al.
Publicado: (2023)

Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases
por: Palimaru, Irina, et al.
Publicado: (2013)

Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis
por: Kim, Seongyeong, et al.
Publicado: (2017)

Effect of Ultra-marathon (308 km) Race on Bone Metabolism and Cartilage Damage Biomarkers
por: Shin, Kyung-A, et al.
Publicado: (2012)

PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma
por: Kim, Hyo Song, et al.
Publicado: (2016)

Extensive Late-Acquired Incomplete Stent Apposition After Sirolimus-Eluting Stent Implantation
por: Choi, Hyun-Chul, et al.
Publicado: (2010)

CERN Bulletin Issue No. 01-02/2015
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ed8squqog19hqoula6nj3jlric